Abstract: Inclusion of alginate in enzyme-conjugate incubation solutions is used to improve performance of immunoassays. The total binding of antibody-signal producing species conjugate is enhanced and the specific binding is enhanced more than the non-specific binding. This allows a lower detection limit to be achieved in these assays.
Abstract: A screening assay for detecting the presence of Pseudomonas bacteria in a test sample comprising isolating the bacteria present in the sample, extracting Azurin protein from the periplasm within the bacteria, reacting the extract with an enzymatically labelled, Azurin-specific antibody and a color-producing substrate specific for the enzyme which is capable of producing a color distinct from the color generated by Azurin and reading the results of the reaction of the sample with the antibody to determine whether the color has been produced whereby the presence of Pseudomonas bacteria in the sample is indicated.
Type:
Grant
Filed:
March 30, 1990
Date of Patent:
May 11, 1993
Assignee:
The United States of America as represented by the Administrator of the National Aeronautics and Space Administration
Abstract: A method for immunochemical determination of a hapten in a sample is disclosed, in which(A) a high-molecular compound to which the hapten is bound (reagent A),(B) insoluble carrier particles carrying thereon an antibody to the hapten (reagent B), and(C) magnetic substance-containing insoluble carrier particles carrying thereon an antibody to an antigenic determinant in the high-molecular compound and different from the hapten (reagent C),are used. These three reagents are dispersed in the sample, then, a magnetic field is applied to separate from the reaction mixture unreacted reagent (C) and agglutinated particles formed from the reagent (B) and the reagent (C) through the reagent (A). The amount of the reagent (B) remaining dispersed in the reaction mixture is measured, thereby determining the extent of competitive inhibition to the agglutination of the reagent (B) and the reagent (C) through the reagent (A) by the reaction between the hapten in the sample and the reagent (B).
Abstract: Antigens or antibodies are detected using a novel membrane based immunoassay. Known antigens or antibodies which will form complexes with antigens/antibodies to be assayed are spot filtered with pressure through a membrane. The membrane, either by itself or attached to a base material as a test strip, is incubated with a test fluid. Consequently, the resulting antibody-antigen complex is incubated directly or after an intermediate anti-antibody incubation with enzyme conjugated immunoglobulin and exposed to substrate which produces a colored insoluble product if the test target is present.
Type:
Grant
Filed:
December 30, 1991
Date of Patent:
April 6, 1993
Assignee:
The United States of America as represented by The Secretary of the Navy
Abstract: A protein having a molecular weight of from about 10,000 to 18,000 daltons, isoelectric points of from about pH 4.0 to 6.5 and having the reversible biological effect of inhibiting aromatase activity in a biological system, and antibodies to the protein, modulate follicular development and spermatogenesis and provide for diagnostic tests of gonadel functions.
Abstract: The present invention is directed to a method for selectively blocking or inactivating glucocorticoid receptors by administering a glucocorticoid receptor blocking effective amount of arsenite or methyl methanethiolsulfonate (MMTS) in a sample. Thus, arsenite and MMTS constitute new, simple, reversible, and inexpensive reagents for assaying glucocorticoid receptors in the presence of other receptors and for eliminating the complications of assaying other receptors in the presence of glucocorticoid receptors.
Type:
Grant
Filed:
September 19, 1990
Date of Patent:
December 22, 1992
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: An in vivo method for preparing, inserting, isolating, collecting and assaying diagnostic ligates present in body fluids. Magnetically responsive particles with attached ligands specific for a particular ligate are introduced into the body fluid. Bonding between the ligand and ligate results in particle/ligand/ligate complexes. The complexes are removed by the application of a magnetic field and the complexes are permitted to cluster. The clusters are then quantitated to determine the concentration of the ligate in the body fluid. Associated materials and devices useful in the practice of this method are also provided.
Type:
Grant
Filed:
February 2, 1989
Date of Patent:
October 27, 1992
Assignee:
University of Connecticut
Inventors:
Edward F. Rossomando, Jane Hadjimichael
Abstract: The invention relates to a process for the stabilization of biologically active substances which are immobilized on a carrier, where the solid phase with the immobilized biologically active substance is contacted for the stabilization with a solution which contains polyanetholesulfonic acid and/or salts thereof. The biologically active substances are, in particular, antibodies.
Type:
Grant
Filed:
June 12, 1990
Date of Patent:
June 30, 1992
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Henning Hachmann, Peter Molz, Stephan Neuenhofer, Gerd Schnorr, Guido Simons, Heinz-Jurgen Skrzipczyk, Kurt E. Weimer
Abstract: A xanthine oxidase enzyme system to provide long lived entities capable of being recognized by a chemiluminescent reagent is disclosed. In the examples provided, a specific binding pair ligand or analyte is coupled with xanthine oxidase, either directly or via a streptavidin bridge. Thereafter, the presence of an analyte can be determined by a chemiluminescent emission upon addition of a signal reagent comprising hypoxanthine, iron EDTA complex and luminol dissolved in barbital buffer. The resulting chemiluminescent signal is stable and detectable for many hours after initiation. The chemiluminescent xanthine oxidase system is particularly useful for immunoassays and DNA probe analysis.
Abstract: A novel immuno-dye reagent capable of detecting the presence of endotoxin in samples has been developed. The immuno-dye reagent comprises a solution of new methylene blue and an anti-endotoxin monoclonal antibody specific to a selected endotoxin. The immuno-dye reagent can be used in an assay to detect endotoxin by reacting the immuno-dye reagent with an endotoxin suspect pH adjusted sample, under hydrophobic conditions. The immuno-dye reagent can also be used in any application where binding of endotoxin is crucial, such as purifying endotoxin-contaminated solutions.
Type:
Grant
Filed:
September 29, 1989
Date of Patent:
March 3, 1992
Assignee:
The United States of America as represented by the Secretary of the Navy
Inventors:
Taffy J. Williams, Che-Hung Lee, Akindele O. Johnson